To counteract the STAT3-induced tumorigenic properties of IL-22, neutrophil-produced IL-22 binding protein (IL-22BP) functions as a soluble receptor that inhibits the binding of IL-22 to its transmembrane receptor, highlighting the potential therapeutic use of IL-22BP in HCC [266]. The gene discussed is IL22RA2; the disease is hepatocellular carcinoma.